Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

JSE Limited : JSE to welcome REITs regime

04/02/2013 | 08:29am US/Eastern
Recommend:
0

Johannesburg, 2nd April 2013 - From yesterday the 1st April 2013 South Africa will implement a local Real Estate Investment Trust (REIT) regime that will usher in a new era for the listed property sector. From this date all property companies currently listed on the JSE either property loan stocks or property unit trusts will convert to a REIT structure and any new listings in this sector will have to comply with JSE REIT listing requirements.

"The REIT structure is in line with international best practice and having a globally understood structure will make our listed property sector much more attractive to foreign investors. The tax advantages of the new structure will also make the listed property sector much more attractive to local investors," says Patrycja Kula Business Development Manager at the JSE. When South African listed property funds convert to this system South Africa will be the 8th largest REIT market. The REITs structure will bring about much needed tax and regulatory changes

This change follows the formal announcement of REIT tax legislation for South Africa, published on 25 October 2012 by National Treasury to introduce this internationally recognised structure in South Africa. Under this new legislation, capital gains tax is no longer payable on disposal of assets and without this tax activity in the sector will increase.

To qualify as a REIT fund, companies need to have:

  • a minimum of R300 million in assets
  • a total debt to asset ratio of no more than 60%
  • 75% income from property rentals
  • a distribution minimum of 75% of the distributable profits (dividends)

For investors, there is certainty in that 75% of all net income is paid out and tax exposure is determined only by the tax status of the recipient. International performance comparisons will be easily made and the investor is protected within an internationally defined and regulated industry.


distributed by
Recommend :
0
React to this article
Latest news
Date Title
1m ago DIRECTV : Special Notice - DIRECTV Satellite Service Renewal
3m ago Modification to a Previous Presolicitation Notice - Federal Insurance and Mitigation Administration (FIMA) - NON-A&E SERVICES
3m ago Presolicitation Notice - Independent Authoritative Assessment of Hospital Care and Medical Services
5m ago SYNOPSYS : Presolicitation Notice - Synopsys, inc Maintenance and Updates for Saber Circuit Simulator
5m ago ROLLS ROYCE : Sources Sought Notice - WLB Controllable Pitch Propeller Hubs
6m ago DUN & BRADSTREET : D&B's U.S. Economic Health Tracker Points to Continued Economic Hesitation despite Pockets of Resilience
7m ago GLOBAL SOURCES BERMUDA : China's premier electronics design show IIC-China opens today in Shenzhen with new product announcements and close to 100 presentations given by global technology leaders over four days
16m ago CN NATIONAL CHEMICAL ENGINEERING : 2014-08-28CNCEC Listed in “2013 Top 100 Jinniu Award for PRC Listed Companies”
16m ago SAMSUNG SDI : 200 teenagers invited to visit the Euiwang Plant of Samsung.. 2014.09.02
16m ago SAMSUNG SDI : Gumi Plant s elected as ‘Company of the Mont.. 2014.09.02
Latest news
Advertisement
Hot News 
TECAN : Presolicitation Notice - Tecan Microplate Reader Equipment and Equipment Maintenance
MICROSOFT : Smart and affordable
WAL MART STORES : Ralph Nader: Democrats Are Doomed – OpEd
EXELIXIS : Announces Results from the COMET-1 Phase 3 Pivotal Trial of Cabozantinib in Men with Metastatic Castration-Resistant Prostate Cancer
AT&T : 4G LTE Available In Tullahoma
Most Read News
1d ago FORMFACTOR : Raises Third Quarter Guidance Range
1d ago STUART OLSON : announces sale of Broda Construction
1d ago EXELIXIS : Announces Results from the COMET-1 Phase 3 Pivotal Trial of Cabozantinib in Men with Metastatic Castration-Resistant Prostate Cancer
1d ago MEDICINOVA : to Present Data on MN-001 (tipelukast) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) During the 18th International Colloquium on Lung and Airway Fibrosis (ICLAF)
1d ago Akzo Nobel CEO solicited for Axalta bid worth more than $7 billion - Bloomberg
Most recommended articles
1d agoDJZambia Copper Miners Say Crippled by Unpaid $600 Million Tax Refund-Mines Body
4d ago S&P 500 edges up to set new record; best month since Feb
22m ago China won't force foreign auto parts makers to form local JVs - EU trade body
1d ago US Dollar Advances to 7-Month High Against Leading Counterparts
1d ago CHINA WON'T FORCE FOREIGN AUTO PARTS MAKERS TO FORM LOCAL JVS : EU trade body
Dynamic quotes  
ON
| OFF